FDA Doubles Estimated Time Needed For DMF Completeness Assessment

FDA now says Type II active ingredient drug master files should be submitted six months before the referencing ANDA to allow enough time for the completeness assessment. Delays could mean refuse-to-receive action for the ANDA.